OverviewSuggest Edit

Pfenex is a clinical-stage biotechnology company developing and commercializing high-value and difficult to manufacture proteins. The Company has developed a high-quality protein production and bioanalytic technology platform approach that allows them to create biosimilars in a highly efficient manner.

Pfenex's patented protein production platform, Pfenex Expression Technology, enables its ability to produce complex proteins relative to other systems. With advantages including quality, stability, solubility, and purity, Pfenex reduces production and development costs that enable the rapid delivery of protein products into clinical development and commercialization.

TypePublic
Founded2009
HQSan Diego, US
Websitepfenex.com
Employee Ratings2.6

Latest Updates

Employees (est.) (Sept 2019)83(+7%)
Job Openings3
Revenue (FY, 2019)$50.3 M(+239%)
Share Price (Sept 2020)$12.7
Cybersecurity ratingAMore

Key People/Management at Pfenex

Martin Brenner

Martin Brenner

Chief Scientific Officer
Shawn Scranton

Shawn Scranton

Chief Operating Officer
Patrick K. Lucy

Patrick K. Lucy

Chief Business Officer
Eef Schimmelpennink

Eef Schimmelpennink

Chief Executive Officer, President, and Secretary
Jason Grenfell-Gardner

Jason Grenfell-Gardner

M.B.A, Chairman
Show more

Pfenex Office Locations

Pfenex has an office in San Diego
San Diego, US (HQ)
10790 Roselle St
Show all (1)

Pfenex Financials and Metrics

Pfenex Revenue

Embed Graph
View revenue for all periods
Pfenex's revenue was reported to be $50.33 m in FY, 2019
USD

Revenue (Q2, 2020)

781.0k

Gross profit (Q2, 2020)

101.0k

Gross profit margin (Q2, 2020), %

12.9%

Net income (Q2, 2020)

(10.3m)

EBIT (Q2, 2020)

(10.3m)

Market capitalization (14-Sept-2020)

435.9m

Closing stock price (14-Sept-2020)

12.7

Cash (30-Jun-2020)

61.0m
Pfenex's current market capitalization is $435.9 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

10.6m9.6m60.2m28.8m14.9m50.3m

Cost of goods sold

7.2m4.6m5.3m5.2m5.0m4.9m

Gross profit

3.4m4.9m54.9m23.6m9.8m45.4m

Gross profit Margin, %

32%52%91%82%66%90%
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

3.3m2.8m2.0m2.3m2.1m2.8m3.1m48.8m2.8m3.0m5.0m3.7m4.2m3.6m10.4m2.8m15.2m682.0k781.0k

Cost of goods sold

2.5m1.6m1.3m921.0k682.0k1.3m1.4m1.3m810.0k905.0k1.8m1.5m924.0k1.5m1.6m1.1m1.1m340.0k680.0k

Gross profit

722.0k1.2m667.0k1.4m1.4m1.5m1.7m47.5m2.0m2.1m3.3m2.2m3.3m2.1m8.8m1.7m14.1m342.0k101.0k

Gross profit Margin, %

22%44%34%60%67%54%54%97%71%70%65%59%78%59%85%60%93%50%13%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

45.7m106.2m81.5m57.7m56.2m55.6m

Accounts Receivable

1.6m

Prepaid Expenses

1.8m1.7m1.9m1.7m1.9m

Inventories

23.0k24.0k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

3.9m51.5m92.0m123.0m115.9m96.5m89.6m93.6m70.2m59.9m48.4m47.1m80.2m67.8m45.8m41.6m32.5m65.6m61.0m

Accounts Receivable

1.4m1.8m

Prepaid Expenses

1.5m426.0k2.1m2.3m2.0m2.1m3.1m2.3m1.8m1.3m1.7m1.6m1.7m2.0m2.1m1.7m2.4m

Inventories

18.0k24.0k21.0k31.0k25.0k
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(9.8m)(28.2m)5.5m(25.7m)(39.6m)1.1m

Depreciation and Amortization

994.0k1.1m1.2m1.4m1.7m1.8m

Inventories

3.0k(1.0k)

Accounts Payable

(675.0k)(243.0k)431.0k628.0k68.0k(1.4m)
USDQ2, 2014

Financial Leverage

-0.3 x
Show all financial metrics

Pfenex Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Pfenex Online and Social Media Presence

Embed Graph

Pfenex News and Updates

Lifshitz Law Firm, P.C. Announces Investigation of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), GCI Liberty, Inc. (NASDAQ: GLIBA), Maxim Integrated Products (NASDAQ:MXIM), National General Holdings Corp. (NASDAQ: NGHC), Pfenex Inc. (NYSE: PFNX), Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), and Varian Medical Systems, Inc. (NYSE: VAR)

NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of CBMG to members of CBMG management. If you are a CBMG investor, and would like...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Pfenex, Inc.

NEW YORK, Aug. 11, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pfenex, Inc. ("PFNX" or the "Company") (NYSE American: PFNX) in connection with the proposed acquisition of the Company by...

Pfenex to Announce Second Quarter Financial Results on August 6

SAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Thursday, August 6, 2020. Pfenex will host a conference call and webcast to discuss its fin…

Thinking about buying stock in Aurora Cannabis, Coca-Cola, Match Group, Pfenex, or RingCentral?

NEW YORK, Oct. 7, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, KO, MTCH, PFNX, and RNG. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis

Pfenex earns a $2.5M milestone payment from Alvogen for U.S. approval

Pfenex to Participate at the William Blair Late-Stage Therapeutics Conference

SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, announced today that Eef Schimmelpennink, …
Show more

Pfenex Blogs

Pfenex Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update

Alvogen is preparing for commercial launch of PF708 upon receiving FDA decision on therapeutic equivalence to Forteo® | Jazz initiated a pivotal Phase 2/3 Study for FDA fast track designated PF743 (JZP-458) for the treatment of ALL/LBL | Earned $31.1 million in development and regulatory milestone p…
Show more

Pfenex Frequently Asked Questions

  • When was Pfenex founded?

    Pfenex was founded in 2009.

  • Who are Pfenex key executives?

    Pfenex's key executives are Martin Brenner, Shawn Scranton and Patrick K. Lucy.

  • How many employees does Pfenex have?

    Pfenex has 83 employees.

  • What is Pfenex revenue?

    Latest Pfenex annual revenue is $50.3 m.

  • What is Pfenex revenue per employee?

    Latest Pfenex revenue per employee is $606.3 k.

  • Who are Pfenex competitors?

    Competitors of Pfenex include Forge Therapeutics, Endologix and CEL-SCI.

  • Where is Pfenex headquarters?

    Pfenex headquarters is located at 10790 Roselle St, San Diego.

  • Where are Pfenex offices?

    Pfenex has an office in San Diego.

  • How many offices does Pfenex have?

    Pfenex has 1 office.